Compare KLTR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | ABOS |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.0M | 197.9M |
| IPO Year | 2021 | 2021 |
| Metric | KLTR | ABOS |
|---|---|---|
| Price | $1.60 | $3.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 349.7K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,854,000.00 | N/A |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $1.06 | $1.21 |
| 52 Week High | $2.05 | $3.60 |
| Indicator | KLTR | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 68.57 |
| Support Level | $1.56 | $2.13 |
| Resistance Level | $1.68 | $3.60 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 38.02 | 74.23 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.